Abstract  by unknown




ptS.W4thAE (%) 10(12) 19 (21.3)
AE 13 24
pta. withheadache (%) 8 (9.6)* 19(21.3)
drop-out(%) 5 (6) 6 (5.6)
EFFICACY reSUlt9
Ischemicthresh. llme (sec.) HR X BP prod.
A B A B
Basal 7.66 7.14 21812 22136
2 weeks 8,86? 8.Z5t 23789t 2322.7t
4 weeka 9.58? 9.lot 24030t 242s4t
6 weeks 9.9ot 9.46t 24569t 24564t
(*p <0.05 AvS B-CHI SQ.; tp < 0.05 vsbasal-ANOVA)
Cono/Uslorr: MC showeda goodsafetyprofile;the incidenceof AEand
particuladyof headachewassignificantlyloweringroupA.
No arrhythmiaswere obsewedand otherAEs occurredin a very low









motility by 11.2%at 42 days. Sinoeconoemsexist on eaferyof early
vasodilationafterMl,weusedtheGISSI-3databaee(19318pta)todescribe
(a)dosesof L usedin the200parficlpatlngCCU(75%of itelianCCU),and
(b)clinicaldeterminantsofLdosesinthefiret4daysandatdischarge.Target
daily L doseby protooolwee5 mgfor days1 and 2, then 10 mg upto 42
days;ptawithsystolicbloodpressure(SSP)s 120mmHgondays1 thru3
couldbe given2.5 rng.MeanL dose(mg)wason day 14.2 + 16(mean+
SD),day2 4.6+ 2.2,day36.3 + 3.5,day46.6 + 3.7,discharge(14days)
7.2 + 4.2.Variablealikelyto influenceL prescribeddosewereintroducedin
a multivariatelogisticmodelandyieidadthefollowingresults:(a)significant
determinantofuseof targetLdoeeondays1tfiru4 (?5 m@day)weshietory
of hypertension(OR1.44,95°76Cl, 1.28-1.80),whileptewithSBPat entry
of 10&120 mmHg(OR0.44,95%Cl 0.40-0.47),andpteaged>70 y (OR
0.85, 95% Ci 0.78-0.95) receivedlowerdoses;(b) determinantof useof
targetL doseat diacharge(210 mglday)was historyof hypertension(OR













Severalreoentstudieshave demonstratedthat, similarto acute Ml and
suddendeath, episodesof myocerdialischemiaalso havea diurnalpet-
tem withan increasedfrequencyanddurationin the morning(8 am-noon)
hours.Baeadon thesedata, it has beensuggestedthat administrationof
antiischemicdrugs beforebedtimemight be of greaterbenefit in raduc-
ing the risk of ischemiain the morning.Accordingly,in this double-biind,
placebo-ocmtrolled,multioanterstudy,we evaiuatedthe effioaoyof onoe-a-
day formulationof diltiazem,D (dilacorXR, Rhone-PouiencRorer)given
eitheras4S0mgdosebetween7% am or betweenS-10 pmin a random-
ized,crossovermanner.Forty-eight-hourambulatoryECGmonitoring(AEM)
wasperformedat baselineand at the end of eachstudyphaea.A total of
88 ptewith establishedCAD,stabieangina,andambulatoryiechemia(22
mink%h) oompletedall phasesof thestudy.At baselineprforto AMdosing
therewasanaverageof 2.1 + 3.2 ischemicepisodes(lEs)accountingfora
meandurationof 49 + 6Srein,andAMdosingwithD significantlyreduoed
theseto 0.9+ 1.4IEsand22+47 rein,respeorively(p < 0.002).Priorto the
PMdosingtheaverageIEswere1.5+ 1.4witha meandurationof 36 + 57
minandthe PMdosingwithD significantlyreducedtheseto 0.8 & 1.4IEs
and20A 42rein,respectively(p < 0.02).overall,D reduoadIEsby45%and
ischemicdurationby40%duringthemonitoringperiod.Compariarrnof AEM
datarevealedthatbothAMand PMdosingwith Dwereequallyeffectivein
reducingthe riskof ischemiain the morninghours,Theseresuksindicate










levelsof ET-1havabeensuggestedto beof importanceinthepathogenesis
of myocerdialischemia.Aimof the presentstudywasto evaluatethe effaot











Anerial 1.48 i 0.2 1.52A0.1
Comnary.sinus 1,53* 0.4 1.56+ 0.3
BseslinePacing
Coronarysinus 2.31 + 0.2 2,33 & 0.4
“hA-CSChange 44,6 ”/0 46,1%
Pacingsfter studydrug
Coronarysinus 2.07 & 0.3 2.32 + 0.4
O/.A-Cc Change 32.7% 45.9%*
Drugvs Basaiins Pacing –11.9”/0 –0.2%”
Values in ngrl;*p <0.01 E vs P; A = Arterial;Cs = Coronary sinue
In conclusion E reduces the ischamia-induoed oardiac release of ET-1.
Thia may contribute to the cardioprotactive effects of the horrnona.
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CardiactroponinI (cTni)has been shownto be a highiyapaoificmarker
of myocerdialiachemiaallowingdetectionof minormyooardialinjuryunde-
tectableby CK-MBmeasurement.We prospectivelystudied60 Pta(64 +




upperlimit of normal= 0.6 j@) and was aaaessed6, 12, 24, 48 end 72
h afteradmission.All Pfshada coronaryangiogramduringhospitalization
withquantitativeangiographicanalysisof theculpritlesionto aeaeesminimal
iumendiameter(MLD),% diameterstenosie(YoDS)and referenoediameter
(RD).Clinioalfaatures,T or STchanges,recurrenceof pain,MLD,RDand
% DSand needfor revascularisationwerecomparedin Ptswithor without
cTnlelevation.
